Abstract
Three new boron compounds, dihydroxy (oxybiguanido) boron (iii) hydrochloride monohydrate (HB), guanidine biboric acid adduct (GB) and hydroxosalicyl hydroxomato boron (iii) (SHB) were studied to observe their antineoplastic effect, if any. Leukemic cells isolated from acute lymphatic leukaemia (ALL) patients and chronic myeloid leukaemia patients (CML) and myeloid leukemia cell lines (HL 60 and U-937) showed cell growth inhibition after treatment with the boron compounds. MTT assay showed that the growth of metabolically active cells was inhibited by treatment with these drugs. The molecular mechanism by which SHB induced apoptosis in immature blast cells was also investigated by ladder formation in gel electrophoresis.
MeSH terms
-
Acute Disease
-
Antineoplastic Agents / pharmacology*
-
Apoptosis / drug effects*
-
Boron Compounds / pharmacology*
-
Cell Division / drug effects
-
Guanidines / pharmacology
-
HL-60 Cells / drug effects
-
HL-60 Cells / pathology
-
Humans
-
Leukemia, Lymphoid / drug therapy*
-
Leukemia, Lymphoid / metabolism
-
Leukemia, Lymphoid / pathology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / drug therapy*
-
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / metabolism
-
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / pathology
-
Tetrazolium Salts
-
Thiazoles
-
Thymidine / metabolism
-
U937 Cells / drug effects
-
U937 Cells / pathology
Substances
-
Antineoplastic Agents
-
Boron Compounds
-
Guanidines
-
Tetrazolium Salts
-
Thiazoles
-
dihydroxy(oxybiguanido)boron (III)
-
guanidine biboric acid adduct
-
thiazolyl blue
-
Thymidine